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Activation of NF-kB in inflammatory breast cancer (IBC) is associated with loss of estrogen receptor (ER) expression, indicating a
potential crosstalk between NF-kB and ER. In this study, we examined the activation of NF-kB in IBC and non-IBC with respect to ER
and EGFR and/or ErbB2 expression and MAPK hyperactivation. A qRT–PCR based ER signature was evaluated in tumours with and
without transcriptionally active NF-kB, as well as correlated with the expression of eight NF-kB target genes. Using a combined ER/
NF-kB signature, hierarchical clustering was executed. Hyperactivation of MAPK was investigated using a recently described MAPK
signature (Creighton et al, 2006), and was linked to tumour phenotype, ER and EGFR and/or ErbB2 overexpression. The expression
of most ER-modulated genes was significantly elevated in breast tumours without transcriptionally active NF-kB. In addition, the
expression of most ER-modulated genes was significantly anticorrelated with the expression of most NF-kB target genes, indicating
an inverse correlation between ER and NF-kB activation. Clustering using the combined ER and NF-kB signature revealed one cluster
mainly characterised by low NF-kB target gene expression and a second one with elevated NF-kB target gene expression. The first
cluster was mainly characterised by non-IBC specimens and IHC ERþ breast tumours (13 out of 18 and 15 out of 18 respectively),
whereas the second cluster was mainly characterised by IBC specimens and IHC ER  breast tumours (12 out of 19 and 15 out of 19
respectively) (Pearson w
2, Po0.0001 and Po0.0001 respectively). Hyperactivation of MAPK was associated with both ER status and
tumour phenotype by unsupervised hierarchical clustering using the MAPK signature and was significantly reflected by overexpression
of EGFR and/or ErbB2. NF-kB activation is linked to loss of ER expression and activation in IBC and in breast cancer in general. The
inverse correlation between NF-kB activation and ER activation is due to EGFR and/or ErbB2 overexpression, resulting in NF-kB
activation and ER downregulation.
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Breast cancer is the most frequent cause of cancer death in
women worldwide (Key et al, 2001) and represents the second
leading cause of cancer death among women in the United States
(National Center for Chronic Disease Prevention and Health
Promotion, 2006) (Key et al, 2001; Dumitrescu and Cotarla,
2005; Draper, 2006). Inflammatory Breast Cancer (IBC) is a
distinct clinical subtype of locally advanced breast cancer (LABC),
with a particularly aggressive behaviour and poor prognosis.
Clinically, IBC typically presents with rapidly progressive
breast erythema, warmth, oedema and induration (Haagensen,
1956, p. 488). At the time of diagnosis, most patients have
axillary lymph node involvement and 1 out of 3 patients have
metastasis in distant organs (Kleer et al, 2000; Lerebours et al,
2005). The characteristic pathology is the invasion of dermal
lymphatics by tumour emboli, however, this is only present in 50–
75% of the cases (Kleer et al, 2000; Low et al, 2004; Lerebours et al,
2005). Hence, IBC is primarily a clinical diagnosis classified as T4d
in the TNM classification of the American Joint Committee on
Cancer (Singletary et al, 2002). Despite advances in multi-
disciplinary treatment, the prognosis of IBC is less favourable
than of non-IBC, with a 3-year survival of about 40% (Lerebours
et al, 2005).
Recently, both in vitro and in vivo experiments have indicated
that the biology of IBC has some important differences with the
biology of other breast carcinomas. Overexpression of the RhoC
GTPase (Van Golen et al, 1999; Van Golen, 2003; Kleer et al, 2004;
Van den Eynden et al, 2004) and loss of WISP3 protein expression
(Van Golen et al, 1999; Kleer et al, 2004) are highly correlated with
the IBC phenotype. It has been demonstrated that overexpression
of the RhoC GTPase is directly and specifically implicated in the
production of angiogenic factors by IBC cells (Van Golen et al,
2000). In human samples, increased angiogenesis in IBC was
evident by both an increased number of microvessels and a higher
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sfraction of proliferating endothelial cells (Colpaert et al, 2003), as
well as increased expression of several angiogenic growth factors
and growth factor receptors in IBC compared to non-IBC (Van der
Auwera et al, 2004). The specific biology of IBC was further
demonstrated by the fact that a molecular signature based on the
differential expression of 756 genes is able to separate IBC from
non-IBC in an unsupervised hierarchical clustering analysis. The
756 genes-based molecular signature was subjected to a detailed
analysis, revealing the presence of several NF-kB target genes and
upstream activators of the NF-kB signalling pathway, with strong
expression in IBC as compared to non-IBC (Van Laere et al, 2005).
The NF-kB signature has been validated using qRT–PCR for
NF-kB target genes and immunohistochemistry and NF-kB
DNA-binding experiments for different NF-kB transcription
factors (Van Laere et al, 2006b).
The activation of NF-kB in breast cancer has been extensively
described in oestrogen receptor negative (ER ) breast tumours
and ER  breast cancer cell lines suggesting an important
inhibitory crosstalk between both signalling pathways (Biswas
et al, 2000, 2001, 2004; Zhou et al, 2005). This inhibitory cross-talk
can be appreciated from the fact that an increase in both NF-kB
DNA-binding activity (Nakshatri et al, 1997; Pratt et al, 2003) and
expression of NF-kB target genes like IL8 (Freund et al, 2004)
coincides with a shift from oestrogen dependence to oestrogen
independence in breast cancer. The inverse correlation between ER
and NF-kB activity is further supported by the fact that some
breast tumours, resistant to the tumoricidal effect of anti-
estrogens, become sensitised to apoptosis and show a reduction
in NF-kB activity after treatment with oestrogen (Jordan, 2004).
This suggests that the proapoptotic effects of oestrogen in these
tumours are mediated through inhibition of NF-kB (Jordan, 2004).
In our previous study, the significant increase in NF-kB target gene
expression was not only linked to the IBC phenotype, but also to
the ER status. In addition, a significantly elevated amount of
transcriptionally active NF-kB dimers in ER  tumours as
compared to ERþ tumours was observed (Van Laere et al,
2006b). The fact that IBC is more often ER  as compared to non-
IBC is probably one of the reasons for increased NF-kB activation
in IBC as compared to non-IBC.
Recent data suggest that all ER  breast tumours arise from
ERþ breast cancer cells that stop expressing ER. Proposed
mechanisms for the origin of ER  breast cancers include that of
pressures being exerted on ERþ cells by oestrogen withdrawal,
hypoxia, or overexpression of epidermal growth factor receptor or
ErbB2 resulting in MAPK hyperactivation (Creighton et al, 2006).
Hyperactive MAPK leads to the loss of ER expression. In addition,
the indirect activation of NF-kB due to MAPK hyperactivity plays a
role in downregulating ER expression (Creighton et al, 2006).
Recently, the importance of hyperactivated MAPK has been
indicated by the fact that an EGFR/ErbB2-induced MAPK
signature was able to correctly predict the ER status in four
independent data sets with accuracies ranging from 68 to 87%
(Creighton et al, 2006). This mechanism can also explain the
apparent inverse correlation between ER and NF-kB activation.
In the present study, we investigated the activation of the NF-kB
transcription factor in breast cancer in terms of ER signalling and
the hyperactivation of MAPK due to EGFR and/or ErbB2
overexpression, with special emphasis on the IBC phenotype. We
demonstrated that, NF-kB activation is not exclusively limited to
IBC but more general to ER  breast tumours. In addition, we
demonstrated that IBC is characterised by MAPK hyperactivation
in comparison to non-IBC, potentially due to overexpression of
EGFR and/or ErbB2. The activation of NF-kB and the frequent ER
independency of IBC tumours can be explained in this context.
Altogether, these data indicate that NF-kB and MAPK might be
therapeutic targets for IBC specifically and more general for ER 
breast tumours as well as for breast tumours with acquired
resistance against hormonal therapy.
MATERIALS AND METHODS
Patients and samples
Tumour samples were obtained from patients with breast
adenocarcinoma treated in the General Hospital Sint-Augustinus,
Wilrijk, Belgium. Each patient gave written informed consent. This
study was approved by the local institutional review board. All
samples were stored in liquid nitrogen within 15min after excision
(median delay of 9min). Breast tumour samples included 17
pretreatment samples of patients with IBC, diagnosed by
strictly respecting the criteria mentioned in the TNM classifica-
tion of the American Joint Committee on Cancer as T4d
(Singletary et al, 2002). The presence of tumour emboli was, as
an isolated pathological finding, not sufficient for the diagnosis of
IBC. Of the 20 non-IBC samples, 10 represented LABC (7 T3, 3 T4),
four samples represented T2-tumours and six represented
T1-tumours. Thirteen patients with non-IBC had pathological
axillary lymph node involvement. Baseline clinicopathologic
characteristics for the IBC and non-IBC patients from which
samples have been used for qRT–PCR analysis and IHC analysis
are provided in Table 1.
Table 1 Clinicopathological characteristics for the study population
PCR (n¼37) cDNA array (n¼34)
Non-IBC
(n¼20)
IBC
(n¼17)
Non-IBC
(n¼18)
IBC
(n¼16)
Age (years)
Median
(range)
61 (42–78) 56 (41–74) 61 (42–78) 56 (41–74)
Histological type
Ductal 18 15 16 14
Lobular 2 2 2 2
Tumour emboli in dermal lymph vessels
Present 2 14 2 13
Absent 18 3 16 3
Grade
a
16 0 5 0
28 8 8 7
36 9 5 9
T-Stadium
16 0 5 0
24 0 3 0
37 0 7 0
4 3 17 3 16
N-Stadium
b
08 0 7 0
1 11 6 10 5
2 1 11 1 11
ER-status
c
ER negative 5 13 4 12
ER positive 15 4 14 4
PR-status
d
PR negative 9 14 7 13
PR positive 11 3 11 3
IBC¼inflammatory breast cancer.
aAccording to the Elston–Ellis modification of the
SBR grading system.
bThe N-Stadium for patients with IBC was determined clinically.
cER status determined using the anti-ER antibody (PharmDX) and a cutoff level of
10% to discriminate between absence or presence of nuclear protein expression.
dPR
status determined using the anti-PR antibody (clone PgR1249) and a cutoff level of
10% to discriminate between absence or presence of nuclear protein expression.
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real-time RT–PCR
For quantitative Real-Time RT–PCR, RNA was isolated as
described before from all samples (Van Laere et al, 2005, 2006b).
One microgram of RNA from 17 IBC samples and 20 non-IBC
samples in total was reverse transcribed into cDNA with random
primers (High Capacity cDNA Archive Kit, Applied Biosystems,
Foster City, CA, USA). PCR primers and Taqman probes for
eight NF-kB target genes (vascular cell adhesion molecule 1
(VCAM1), CC chemokine receptor 5 (CCR5), superoxide dis-
mutase 2 (SOD2), interleukin 15 (IL15), cathepsin B (CTSB),
interferon regulatory factor 7 (IRF7), guanylate-binding protein 1
(GBP1), CD48 antigen (CD48)), ER-a, ER-band 11 putative ER
target genes (PR (PGR), GATA-binding protein 3 (GATA3), mucin
1 (MUC1), x-box binding protein 1 (XBP1), oncogene MYB (MYB),
B-cell translocation gene 2 (BTG2), transforming growth factor b 3
(TGFb3), Ras-associated protein RAB31 (RAB31), START domain
containing 10 (STARD10), hydroxysteroid dehydrogenase 17 b4
(HSD17b4) and TRIpartite motif-containing protein 25 (TRIM25))
and two housekeeping genes were purchased as assays-on-demand
products for gene expression (Applied Biosystems). Putative ER
target genes were selected based upon a constitutive overexpres-
sion in ERþ breast tumours in three independent genome–wide
breast cancer profiling studies (Abba et al, 2005). 18S ribosomal
RNA and b-actin were used as housekeeping genes to control for
reverse transcriptase efficiency, RNA degradation, PCR inhibition
and RNA input. Human Universal Reference RNA (Stratagene, La
Jolla, CA, USA) was used as calibrator to calculate relative gene
expression for the above-mentioned genes. Quantitative real-time
RT–PCR was performed on the ABI 7700 Sequence Detector
(Applied Biosystems). All PCRs were performed in duplicate.
Relative Gene Expression (RGE) was calculated with the 2-ddCt
method (Livak and Schmittgen, 2001) as described before (Van
Laere et al, 2005, 2006b).
Immunohistochemistry
For NF-kB, EGFR and ErbB2, antibodies purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) were used for
immunohistochemical (IHC) staining of RelA (clone C-20,
sc-372), RelB (clone C-19, sc-226), NFkB1 (clone C-19, sc-1190),
NFkB2 (clone K-27, sc-298), cRel (clone B-6, sc-6955), EGFR (clone
1005, sc-03) and ErbB2 (clone F-11, sc-7301). Formalin-fixed,
paraffin-embedded tissue sections from 17 IBC tumours and 20
non-IBC tumours were rehydrated through sequential changes of
alcohol and distilled water. Antigen retrieval was performed for
30min in citrate buffer (pH 6) for RelA, RelB, NFkB1, NFkB2
and EGFR at 951C. For cRel and ErbB2, antigen retrieval was
performed for 30min in Tris–EDTA buffer (pH 9) at 951C.
Sections were incubated for 1h at room temperature using a
dilution of respectively 0.2, 4.0, 1.3, 2.7, 2.0, 8.0 and 4.0mgml
 1.
The Dako Envision system on the Dako Cytomation autostainer
was used for visualisation of the antibody binding. Tissue sections
were counterstained using haematoxylin and mounted for light
microscopy. For NF-kB, hot spots with nuclear staining were
searched for in each tissue section and within these hot spots a
total number of 500 nuclei was counted at a magnification of
 400. Transcriptionally active NF-kB dimers have been deter-
mined as described before (Van Laere et al, 2006b). The HER2/neu
score using the HercepTest (DakoCytomation, Glostrup, Denmark)
was interpreted on a 0–3 score (0¼no staining or membranous
staining in less than 10% of tumour cells; 1¼faint or barely
perceptible partial membranous staining in more than 10% of
tumour cells; 2¼weak to complete membranous staining in more
than 10% of tumour cells; 3¼strong complete membranous
staining in more than 10% of tumour cells). Based on this score,
the HER2/neu status was determined: Score 0–1 was considered
negative, Scores 2 and 3 was considered positive. For EGFR,
the same scoring system was used (Van den Eynden et al, 2004).
Immunohistochemical overexpression of ErbB2 (2þ or 3þ) was
confirmed by FISH.
For ER quantification, the ER PharmDX (Dako) assay was used.
The ER/PR PharmDX assay is an FDA-approved assay, which
consists of a cocktail of two mouse monoclonal antibodies to ER
(clones 1D5 and ER-2-123), a negative reagent control containing
appropriate Ig concentrations equivalent to the primary anti-
bodies, and cell line control slides. Each cell line control slide
contains sections of two pelleted formalin-fixed, paraffin-
embedded cell lines, which represent a moderate level of ER and
PR protein expression (cell line CAMA-1) and a negative cell line
(cell line HT-29). Formalin-fixed and paraffin-embedded tissue
sections were rehydrated through sequential changes of alcohol
and distilled water. Antigen retrieval was performed at 1251C
during 5min in a pressure cooker using Target Retrieval Solution
(Dako) followed by cooling down the pressure cooker during
30min without venting of pressure. Tissue sections were incubated
during 30min at room temperature. Again, the Dako Envision
system on the Dako Cytomation autostainer was used for
visualisation of the antibody binding and tissue sections were
counterstained using haematoxylin and mounted for light micro-
scopy. A tumour sample was regarded positive when at least 10%
of all tumour cells on the slide showed nuclear staining.
cDNA microarrays
cDNA microarrays have been executed as described before
(Van Laere et al, 2005) on the same patients except for one IBC and
two non-IBC breast tumours. High-quality RNA was reverse
transcribed, amplified and Cy5 labelled using the Amino
Ally MessageAmp aRNA Kit (Ambion Inc., Austin, TX, USA).
Universal Human Reference RNA (Stratagene) was processed
similarly and Cy3 labelled for competitive hybridisation.
cDNA chips were obtained from the Sanger Center and hybridised
during 16h at 471C in a volume of 40ml. Information regarding
the clone set and the microarray production can be obtained from
the World Wide Web: www.sanger.ac.uk/Projects/Microarrays.
After hybridisation, slides were washed and scanned imme-
diately using ScanArray software. Data were generated using
Quantarray software and analysed using GeneSpring (Agilent
Technologies, Palo Alto, CA, USA). The methodology has been
described in Van Laere et al (2005). Baseline clinicopathologic
characteristics for the IBC and non-IBC patients from which
samples have been used for cDNA microarray analysis are
provided in Table 1.
EGFR, ErbB2, MEK and RAF gene expression signatures,
described by Creighton et al (2006), were mapped onto our
tumour data set using the Locus Link ID resulting in the
identification of 54, 55, 50 and 56 common genes respectively.
These genes were combined into a MAPK signature of 223 genes
represented by 283 clones in our IBC/non-IBC data set (Gene list
available as Supplementary information). This MAPK signature
was then analysed using Pathway-Express (http://vortex.cs.wayne.
edu/projects.htm) to investigate which pathways are over-repre-
sented in this gene list. The performance of this MAPK signature to
discriminate between ERþ and ER  samples was tested on the
Sotiriou data set (Sotiriou et al, 2003). Therefore, we submitted the
Sotiriou series of 99 breast tissue samples to hierarchical clustering
based on the expression of the 223 gene set. Normalised and log2
transformed expression data for 223 genes were extracted, median-
centred on genes and analysed using unsupervised hierarchical
clustering with Pearson correlation as similarity metric. Clustering
was visualised using GeneSpring.
Next, to investigate common biological themes in our own IBC/
non-IBC data set defined by the MAPK signature, unsupervised
hierarchical clustering, using centroid linkage clustering with the
NF-jB/ER crosstalk in inflammatory breast cancer
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Global views of the variation in gene expression among the
different breast cancer samples defined by the MAPK signature
were obtained using principal component analysis on our IBC/
non-IBC data set, with the MAPK signature as input data set.
Statistical analysis
All statistical analysis, except for microarray analyses, have
been performed in SPSS (SPSS Inc., Version 12.0, Chicago, IL,
USA). Gene expression differences or differences in the percent-
age of immunostained tumour cell nuclei between two conditions
of interest were analysed using the Mann–Whitney U-test.
Correlations between two binary variables were examined using
a Pearson w
2 test. Correlations between gene expression data
were calculated using the Spearman correlation coefficient.
Differences or correlations were considered significant when the
P-value was below 0.05. To investigate common biological themes
defined by the expression of ER-a, ER-b, ER target genes and
NF-kB target genes, unsupervised hierarchical clustering has been
executed using gene expression data for all NF-kB and ER target
genes. Correlations between the clustering patterns and the ER
status or the breast tumour phenotype were investigated using a
Pearson w
2 test.
RESULTS
Increased activation of NF-jBi nE R   breast tumours
compared to ERþ breast tumours
We compared the expression of eight NF-kB target genes in ERþ
and ER  breast tumours. Median gene expression levels for all NF-
kB target genes were elevated in ER  breast tumours compared to
ERþ breast tumours. For 6 out of 8 NF-kB target genes the
differences in gene expression between ERþ and ER  breast
tumours reached significance. Gene expression data for all NF-kB
target genes in ER  and ERþ breast tumours are presented as a
scatter plot in Figure 1A. Median gene expression values for the
NF-kB target genes in ER  and ERþ breast tumours are indicated
by a horizontal bar.
We observed a significant difference between the percentage
immunostained nuclei for NFkB1 between ERþ (42.20%) and
ER  (61.20%) breast tumours (P¼0.002) For RelB, a trend
towards a significant difference in the percentage of immunos-
tained nuclei was observed (RelB immunostained nuclei in ERþ
breast tumours: 29.60%, RelB immunostained nuclei in ER  breast
tumours: 52.30%; P¼0.092). For RelA, cRel and NFkB2, no
significant difference was found for the percentage of immunos-
tained nuclei between ER  and ERþ breast tumours. Next, we
looked for transcriptionally active NF-kB dimers in ER  and ERþ
breast tumours. Therefore, we dichotomised the percentage of
immunostained nuclei for each NF-kB transcription factor relative
to a cutoff level of 50%. Then, for each sample in our study, we
identified transcriptionally active NF-kB dimers by means of
examining coexpression of the members of the NF-kB transcrip-
tion factor family. The detailed methodology was previously
described and validated (Van Laere et al, 2006b). Hence, we
identified 12 out of 18 ER  breast tumours with transcriptionally
active NF-kB compared to only 1 out of 19 ERþ breast tumours
with transcriptionally active NF-kB( k¼ 0.609, Po0.0001).
Activation of ER and NF-jB transcription factors
is inversely correlated
To further investigate the inverse relationship between NF-kB
signalling and ER signalling, the expression of ER-a, ER-b and 11
putative ER target genes was compared between tumours with
and without transcriptionally active NF-kB dimers present. Out of
11 ER target genes, four ER target genes showed significant
differences between tumours with and without transcriptionally
active NF-kB: GATA3 (P¼0.001), MYB (P¼0.004), HSD17b4
(P¼0.030) and STARD10 (P¼0.013). For XBP1 (P¼0.083), BTG2
(P¼0.072) and RAB31 (P¼0.053) a trend towards significant
overexpression was observed. For MUC1 (P¼0.200), TGFb3
(P¼0.236), TRIM25 (P¼0.937) and PGR (P¼0.132) no
significant differences were observed. The median gene expression
levels were elevated in IHC NF-kB – tumours compared to
IHC NF-kBþ tumours for all ER target genes, except TRIM25.
In addition, median gene expression levels for ER-a were
significantly elevated in IHC NF-kB – breast tumours compared
to IHC NF-kBþ breast tumours (P¼0.003). However, gene
expression data for ER-b was significantly upregulated in IHC
NF-kBþ breast tumours compared to IHC NF-kB  breast
tumours (P¼0.023). Gene expression data for different ER target
genes in NF-kBþ and NF-kB  breast tumours are displayed in
Figure 1B. Median gene expression values for the different ER
target genes in NF-kBþ and NF-kB  breast tumours are indicated
by a horizontal bar.
NF-kB target gene expression data were correlated with gene
expression data for ER-a, ER-b and 11 ER target genes using
Spearman correlation coefficients. Data are represented in a
heatmap format (Figure 2), in which correlation coefficients are
colour coded, with red indicating a positive correlation coefficient
and green indicating a negative correlation coefficient. Colour
saturation indicates the strength of the correlation coefficient. All
NF-kB target genes and most ER target genes are strongly
correlated with each other, indicated by the red squares in the
heatmap at the point of intersection between the ER target
genes on the one hand and NF-kB target genes on the other. Out of
28 comparisons between NF-kB target genes and 78 comparisons
between ER-a, ER-b and 11 ER target genes, respectively 28 and 67
comparisons were positively correlated and in respectively
96 and 62% of the cases, the positive correlation coefficient
reached significance (positive Spearman correlation coefficients
ranging from 0.285 to 0.879). Interestingly, ER-b was antic-
orrelated with ER-a and 7 out of 11 ER target genes, with
anticorrelation coefficients reaching significance in four compar-
isons. Most of the NF-kB and ER target genes are anticorrelated,
indicated by the green squares in the heatmap at the point of
intersection between the ER and NF-kB target genes. In total, 104
comparisons have been made between ER and NF-kB target genes,
from which 77 were anticorrelated and in 40% of the cases the
anticorrelation was significant (negative Spearman correlation
coefficients ranging from  0.283 to  0.584). These data indicate
an inverse correlation between the activation of the NF-kBo n
the one hand and ER on the other. Gene expression data for ER-b
were positively correlated with gene expression data for all NF-kB
target genes, and correlation coefficients reached significance in
five comparisons.
We then applied unsupervised hierarchical clustering to the ER
and NF-kB target gene expression data to investigate common
biological themes defined by the combined ER and NF-kB
signature. The clustering output is displayed in Figure 3. Two
major sample clusters have been identified, as well as two major
gene clusters. The gene clusters represented the NF-kB target
gene signature on the one hand and the ER target gene signature
on the other hand. A first sample cluster was characterised
by an increased expression of the NF-kB signature and a
decreased expression of the ER signature. A second sample
cluster was characterised by an increased expression of the ER
target gene signature and a decreased expression of the NF-kB
target gene signature. The first sample cluster was characterised
by an increased amount of IBC samples. Out of 17 IBC samples,
12 IBC samples belonged to the NF-kB positive cluster whereas
five IBC samples belonged to the NF-kB negative cluster. Out
of 20 non-IBC samples, 13 non-IBC samples belonged to the
NF-jB/ER crosstalk in inflammatory breast cancer
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Molecular DiagnosticsNF-kB negative cluster and seven non-IBC samples belonged
to the NF-kB positive cluster (Pearson w
2; P¼0.001). However,
when looking at the ER status, out of 19 samples in cluster
1, 15 samples were identified as being ER . Out of 18 samples in
cluster 2, again 15 samples were identified as being ERþ (Pearson
w
2; Po0.0001), indicating that elevated NF-kB activation is
more common in ER  breast tumours, independent of the
IBC of non-IBC phenotype and that the frequent activation
of NF-kB in IBC is caused by the frequent ER negativity of
IBC specimens.
EGFR/ErbB2-MAPK hyperactivation leads to NF-jB
activation and ER downregulation
The MAPK signature composed of 223 genes up- or downregulated
in MCF7 cell lines, after transfection with EGFR (þEGF), ErbB2,
RAF and MEK was first analysed using Pathway-Express to
investigate which signal transduction pathways are represented
in this gene list. Not surprisingly, the MAPK pathway was
most significantly linked to the MAPK signature (Rank 1,
Po0.001). However, other important signal transduction
pathways were also represented in the MAPK signature among
which: Wnt signalling pathway (Rank 5, P¼0.005), Notch
signalling pathway (Rank 6, P¼0.006), VEGF signalling pathway
(Rank 7, P¼0.008) and the Toll-like receptor signalling pathway
(Rank 10, P¼0.009).
Next, we tested the MAPK signature for performance by
unsupervised hierarchical clustering on the Sotiriou data (Sotiriou
et al, 2003) set to identify ER status. The output of the clustering
analysis is shown in Figure 4A. We identified one large cluster that
was mainly composed of ERþ specimens (58 out of 63) and two
smaller clusters mainly composed of ER  specimens (29 out of 36)
(Pearson w
2, Po0.0001). In total, the performance of the
MAPK signature in predicting the ER status by unsupervised
analysis of the Sotiriou data set (Sotiriou et al, 2003) was 88%. This
clearly demonstrated that the MAPK signature is capable of
predicting ER status.
Next, the MAPK signature was applied onto our own IBC/non-
IBC data set (Van Laere et al, 2005) by unsupervised hierarchical
clustering analysis. The output of the clustering analysis is shown in
Figure 4B. We identified two clusters, one which was mainly
enriched in ER  breast cancer specimens (9 out of 12) and a second
which was mainly enriched in ERþ breast cancer specimens (15 out
of 22) (Pearson w
2, Po0.001), resulting in an accurate prediction of
IHC ER status in 71% of the cases. However, when looking at the
distribution of the different IBC/non-IBC samples over the different
clusters, we found that the first cluster was exclusively composed of
IBC specimens (12 out of 12), whereas the second cluster was
mainly composed of non-IBC specimens (18 out of 22) (Pearson w
2,
Po0.0001), resulting in an accurate prediction of the tumour
phenotype in 88% of the cases. We then performed a principle
component analysis with the MAPK signature as input data set to
obtain global views of the variation in the IBC/non-IBC data set,
defined by the MAPK signature. We identified that the expression of
the first metagene, being the first principal component generated by
the principal component analysis, accounting for approximately
44% of the total variation seen in this data set, was significantly
overexpressed in IBC (median: 1.127) compared to non-IBC
ESR1
ESR2
GATA3
MUC1
XBP1
MYB
BTG2
TGFb3
RAB31
STARD10
HSD17b4
TRIM25
SOD2
CD48
IRF7
CTSB
VCAM1
GBP1
IL15
CCR5
E
S
R
1
E
S
R
2
G
A
T
A
3
M
U
C
1
X
B
P
1
M
Y
B
B
T
G
2
T
G
F
b
3
R
A
B
3
1
S
T
A
R
D
1
0
H
S
D
1
7
b
4
T
R
I
M
2
5
S
O
D
2
C
D
4
8
I
R
F
7
C
T
S
B
V
C
A
M
1
G
B
P
1
I
L
1
5
C
C
R
5
P
G
R
PGR
Figure 2 Heatmap comparing gene expression profiles of each gene in the ER/NF-kB signature with each other. Correlation coefficients are colour
coded, with red indicating positive correlation coefficients and green indicating negative correlation coefficients. Colour saturation indicates the strength of
the correlation coefficients. The blue arrow indicates the ER target genes, the yellow arrow indicates the NF-kB target genes. Two red squares are clearly
visible at the points of intersection between the ER target genes on the one hand and the NF-kB target genes on the other, indicating positive correlations
(dashed squares). Green squares are visible at the points of intersection between ER and NF-kB target genes, indicating inverse correlations (straight
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s(median: 0.904) (Po0.001). The expression profile of the first
metagene is drawn underneath the clustering output in Figure 4B.
The red line indicated a relative gene expression level of 1. Most IBC
specimens have a strongly elevated expression for the first metagene
(above 1) whereas most non-IBC specimens have a reduced
expression for the first metagene (beneath 1).
Next, we analysed if the samples with a strong expression for the
first metagene were also characterised by an overexpression of
EGFR and/or ErbB2. Therefore, we performed IHC for EGFR and
ErbB2 (Figure 4C) and scored membranous staining. IHC data
were then mapped onto the dendrogram and the results are shown
in Figure 4B. Most samples characterised by an elevated expression
for the first metagene were also characterised by an overexpression
of EGFR and/or ErbB2 as shown in Figure 4B. The expression
of the first metagene was significantly elevated in tumours
characterised by EGFR/ErbB2 overexpression (median: 1.109)
compared to tumours without overexpression of EGFR or ErbB2
(median: 0.909) (P¼0.004).
Finally, IHC data for EGFR and/or ErbB2 overexpression were
correlated with tumour phenotype (IBC/non-IBC), ER status and
the presence of transcriptionally active NF-kB dimers. The
presence of membranous staining for EGFR and/or ErbB2 was
significantly correlated with tumour phenotype. We identified 13
out of 17 IBC tumours with EGFR and/or ErbB2 over-
expression compared to only one non-IBC tumour with EGFR
and/or ErbB2 overexpression (k¼0.742, Po0.0001). Out of 13
samples with transcriptionally active NF-kB dimers, nine showed
overexpression of EGFR and/or ErbB2 whereas out of 24
tumours without transcriptionally active NF-kB dimers only five
showed overexpression of EGFR and/or ErbB2 (k¼0.476,
P¼0.004). The overexpression of EGFR and/or ErbB2 was also
significantly anticorrelated with ER status. Out of 19 ERþ breast
tumours 15 showed no overexpression of EGFR and/or ErbB2
whereas 10 out of 18 ER  breast tumours showed over-
expression of EGFR and/or ErbB2 (k¼ 0.343, P¼0.031). Using
tumour phenotype (IBC or non-IBC), ER expression and presence
of transcriptionally active NF-kB as independent variables
and EGFR and/or ErbB2 overexpression as dependent variable,
a logistic regression was performed. Tumour phenotype was
identified as the most predictive parameter to discriminate
between tumour samples with EGFR and/or ErbB2 overexpression
and without EGFR and ErbB2 overexpression (b¼18.039;
P¼0.038). The presence of transcriptionally active NF-kB
(b¼7.720; P¼0.092) and expression of ER (b¼ 6.800;
P¼0.122) were both not significantly associated with EGFR and/
or ErbB2 overexpression in this model.
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Figure 3 Unsupervised hierarchical clustering using the ER/NF-kB signature. Two clusters are clearly visible, indicated by the black and the
grey bar underneath the dendrogram. Gene expression data are represented in matrix format, with rows indicating genes and columns indicating
samples. Overexpressed genes are colour coded red and repressed genes are colour coded green. Colour saturation indicates the level of
overexpression or repression. The NF-kB signature is indicated by a yellow bar and the ER signature is indicated by a blue bar (right of the matrix).
Tumour type (IBC or non-IBC) and ER status (ERþ or ER ) is represented underneath the dendrogram using purple (IBC and ER  respectively)
and brown (non-IBC and ERþ respectively) bars. The cluster indicated by the black bar contains 12 out of 19 IBC samples and 15 out of 19
ER  breast tumour samples. The cluster indicated by the grey bar contains 13 out of 18 non-IBC samples and 15 out of 18 ERþ breast tumour
samples.
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sDISCUSSION
The activation of NF-kB has been described previously in human
breast cancer and breast cancer cell lines and has been specifically
linked to ER independency. Biswas et al reported that NF-kBi s
activated more often in ER  human breast tumours compared
with ERþ breast tumours and most predominantly in ER  and
ErbB2þ breast tumours (Biswas et al, 2004). Zhou et al studied
the activation of NF-kB in two groups of ERþ breast tumours.
Early-stage primary breast cancer selected for lower ER content
showed two- to fourfold increased NFkB1 and RelA DNA binding
over a second set of primary breast cancer with higher ER content.
This demonstrates that the level of NF-kB activation is inversely
correlated with ER content (Zhou et al, 2005). In a recent study, we
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MAPK+ 8/12   (66.67%) 5/22   (22.73%)
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Figure 4 The performance of the MAPK signature for prediction of ER status was validated using the Sotiriou data set (A). Unsupervised
hierarchical clustering was executed. Data are represented in matrix format, with rows indicating genes and columns indicating samples. Over-
expressed genes are colour coded red and repressed genes are colour coded green, missing values are colour coded grey. Colour saturation
indicates the level of overexpression or repression. Two clusters have been identified indicated by the black and grey bars underneath the dendrogram.
ER status is represented by the purple (ERþ) and brown (ER ) bar. The MAPK signature was then applied onto our own IBC/non-IBC expression
data set using unsupervised hierarchical clustering (B). Again, data are represented in a matrix format, with rows representing genes and
columns representing samples. Overexpressed genes are colour coded red and repressed genes are colour coded green. The level of overexpression
or repression is represented by the colour saturation. Two clusters have been identified indicated by the black and grey bars underneath the
dendrogram. Tumour type (IBC or non-IBC), ER status (ERþ or ER ) and MAPK status (presence or absence of EGFR and/or ErbB2 overexpression)
are indicated using brown (IBC, ER  and presence of EGFR and/or ErbB2 overexpression respectively) and purple (non-IBC, ERþ and absence
of EGFR and/or ErbB2 overexpression respectively) bars. The cluster indicated by the black bar contains 15 out of 22 ERþ breast tumour
samples, 18 out of 22 non-IBC specimens and 17 out of 22 MAPK-negative breast tumour specimens. The cluster indicated by the grey bar contains 9
out of 12 ER  breast tumour samples, 12 out of 12 IBC specimens and 8 out of 12 MAPKþ breast tumour specimens. The expression profile
of the first metagene, representing approximately 44% of the total variation seen within this data set, is shown underneath the matrix. The red line
indicates a relative gene expression level of 1 (reference). Microphotographs showing membranous staining for EGFR (left) and ErbB2 (right) are
displayed in (C).
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sdescribed that the expression of several NF-kB target genes was
significantly elevated in IBC compared to non-IBC (Van Laere
et al, 2006b). In addition, the increased activation status
of NF-kB in IBC was confirmed by immunohistochemistry and
DNA-binding experiments. Considering the fact that the activation
of NF-kB is generally linked to ER independency, these findings
can be explained by the fact that, compared to non-IBC, IBC has a
low frequency of ERþ tumour specimens. In this study, we
show that the activation of NF-kB is indeed more generally linked
to breast tumours without ER protein expression than specifically
to the IBC phenotype. Breast tumours with transcriptionally
active NF-kB show reduced expression of most ER target
genes, whereas ERþ breast tumours show reduced expression of
most NF-kB target genes. The expression of ER-a and most
ER target genes is anticorrelated with the expression of most
NF-kB target genes in our data set of 37 IBC and non-IBC
breast tumours, indicating an inverse correlation between ER and
NF-kB activation. By means of unsupervised hierarchical cluster-
ing using the combined ER and NF-kB data set we identified two
sample clusters, one of which was characterised by a low
expression of ER target genes and high expression of NF-kB target
genes, and a second with high expression of ER target genes
and low expression of NF-kB target genes. The distribution of the
different tumour samples over both clusters showed that the
activation of NF-kB was not exclusively linked to the IBC
phenotype, but more generally to breast tumours without ER
expression at protein level.
Several mechanisms resulting in the inverse correlation between
NF-kB activation and ER activation have been proposed (Kalaitzidis
and Gilmore, 2005). ER has been shown to block NF-kB activity
at several steps: (a) it can inhibit the IKK activity; (b) it can inhibit
degradation of IkB; (c) it can block DNA binding by NF-kB; (d) it
can bind coactivators and compete with NF-kB for coactivators
binding; and (e) it can directly bind to DNA-bound NF-kBt o
inhibit NF-kB-mediated transcriptional activation. In addition, the
cross-coupling between ER and NF-kB also results in reduced
activity of promoters with ER binding sites (Stein and Yang, 1995).
The inverse correlation between NF-kB activation and ER
activation can also be explained alternatively. Recent evidence
suggests that all ER  breast tumours arise from ERþ breast
tumour cells that stop expressing ER-a (Creighton et al, 2006). One
of the reasons for the downregulation of ER-a is the over-
expression of EGFR and/or ErbB2 resulting in the hyperactivation
of MAPK (Oh et al, 2001). This mechanism possibly involves the
activation of NF-kB (Holloway et al, 2004). The importance of
hyperactivated MAPK for the generation of ER  breast tumours
has been demonstrated by the fact that a MAPK signature is able to
discriminate between ERþ and ER  breast tumours in four
independent data sets with accuracies ranging from 68 to 87%
(Creighton et al, 2006). The application of a MAPK signature to
our own IBC/non-IBC data set resulted in the correct prediction
of ER status in 70% of the cases. However, the separation
between IBC and non-IBC samples, based on the MAPK signature,
was even more strict, with almost all IBC specimens falling
together in one cluster and almost all non-IBC specimens falling
together in a second cluster, independent of ER status. The
presence of the VEGF, Wnt, Notch and Toll-like Receptor
signalling pathways in the MAPK signature may account for
the clustering pattern. Previously, it has been extensively
demonstrated that IBC is characterised by increased angiogenesis
(Van der Auwera et al, 2004) for which VEGF signalling is very
important. Additionally, microarray experiments have shown
that Wnt and Notch signalling pathways are represented in an
IBC gene expression signature (Van Laere et al, 2005). In
addition, the Toll-like Receptor signalling pathway, also linked to
the IBC gene expression signature (Van Laere et al, 2005),
leads to the activation of NF-kB, a hallmark of IBC (Van Laere
et al, 2006b). Altogether, this clustering pattern again underscores
the distinct biological phenotype of IBC. Additionally, these results
agree with our findings that IBC more often displays features
of the Basal-like or ErbB2-overexpressing cell-of-origin breast
cancer subtypes (Van Laere et al, 2006a) as described by Perou
et al (2000). Breast tumours belonging to these subclasses more
often demonstrate respectively EGFR and ErbB2 overexpression
(Nielsen et al, 2004).
From the expression of the first metagene in IBC and non-IBC
we learned that IBC is characterised by a more frequent
MAPK hyperactivation, which is reflected by the frequent
overexpression of EGFR and/or ErbB2 in IBC compared to
non-IBC. Previous studies have shown, that the MAPK pathway
is involved in RhoC GTPase induced motility, invasion and
angiogenesis in IBC (Van Golen et al, 2002). Other studies
have shown that the stimulatory effect of the RhoC GTPase-
activity on tumour growth depends on NF-kB activity (Benitah
et al, 2003). One of the first molecular alterations characterised
in IBC was the overexpression of RhoC (Van Golen et al,
1999). In combination with our data, this suggests that IBC is
generally characterised by overexpression of EGFR and/or ErbB2,
leading to MAPK-induced activation of NF-kB, which then in turn
results in RhoC overexpression and loss of ER expression.
However, these associations have only been marginally under-
scored using a multivariate regression model, except for the
association between tumour phenotype and EGFR and/or ErbB2
overexpression. This indicates that more elaborate research
using a larger amount of breast tumours is needed to confirm
the observed associations. In addition, it should be noted that
our findings have been based upon correlations between gene
expression and protein expression data. Further investi-
gation, using IBC and non-IBC cell lines, should be performed to
mechanistically confirm the proposed interactions. Never-
theless, our data are in close agreement on previously
published research on NF-kB activation in breast cancer, both
in cell lines and in human samples (Biswas et al, 2000; Zhou
et al, 2005).
The absence of NF-kB activation in ERþ cancers remains
remarkable, and is explained by specific inhibitory crosstalk
between NF-kB and ER signalling. The precise intersection
of ER with the NF-kB pathway is not clear, and may be at multiple
points (as discussed above). The specific inactivation of NF-kB
signalling by ER and oestrogen implies a specific mechanism
that is selected by ERþ breast cancers. During endocrine
therapy, resistance invariably develops. For agonist–antagonist
drugs, such as Tamoxifen, a shift from antagonist to agonist
activity appears to be an important mechanism of resistance.
For newer aromatase inhibitors, which deprive tumours of
oestrogen, resistance mechanisms are not yet described. NF-kB
activation, through escape from tonic inhibition by oestrogen,
is a reasonable candidate mechanism for resistance to
oestrogen deprivation. Hence, as suggested by our data, NF-kB
can be an important therapeutic target for patients treated with
aromatase inhibitors developing resistance to oestrogen depriva-
tion as well as for patients having EGFR and/or ErbB2
overexpression.
In conclusion, the MAPK signature performs better in separat-
ing IBC from non-IBC tumours than in distinguishing ER  from
ERþ breast tumours. This despite the clearly demonstrated
performance of the MAPK signature in distinguishing ER  from
ERþ breast tumours in the Sotiriou data set. The elevated
expression of the MAPK signature, characterizing IBC, is reflected
by the high percentage of EGFR and/or ErbB2 overexpressing
IBC tumours, which potentially leads to the frequent ER
independency of IBC, as well as to an increased activation of
NF-kB, accounting for the inverse interaction between NF-kB
and ER activation. It should be noted that, the increased activation
of NF-kB is not exclusively linked to the IBC phenotype, but
more generally to ER-independent breast tumours, which
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shave a more frequent EGFR and/or ErbB2 amplification, hence
breast tumours belong to the Basal-like and ErbB2-overexpressing
cell-of-origin subtypes respectively. The relationship between
EGFR and/or ErbB2 overexpression, MAPK hyperactivation, NF-
kB transcriptional activity and loss of ER protein expression in
Basal-like or ErbB2-overexpressing breast tumours is currently
under investigation.
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